While many big companies believe science is key to continue innovating and expanding (as is exemplified by substantial R&D budgets), I am convinced that SynBio tools have the potential to boost all areas of innovation.
The proposed transaction would represent the first cornerstone of eureKING’s project to pursue bolt-on acquisitions to add innovative companies from the fast growing biotherapies CDMO segment to its platform to create a bio-CDMO leader and which could result in additional transactions. These transactions may be announced before the completion of the proposed transaction.
eureKING has a clear and identified roadmap to bolster Skyepharma’s technology platform to consolidate the highly fragmented European market in biomanufacturing capacity, such as state-of-the-art facilities to manufacture cell and gene therapies in Europe.
Luxembourg | France | Belgium
Subscribe to our news to keep in touch
